0001415889-24-029143.txt : 20241212 0001415889-24-029143.hdr.sgml : 20241212 20241212170009 ACCESSION NUMBER: 0001415889-24-029143 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241210 FILED AS OF DATE: 20241212 DATE AS OF CHANGE: 20241212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Townsend Richard Nolan CENTRAL INDEX KEY: 0001995218 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41855 FILM NUMBER: 241545687 MAIL ADDRESS: STREET 1: C/O LEXEO THERAPEUTICS, INC. STREET 2: 345 PARK AVENUE SOUTH, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc. CENTRAL INDEX KEY: 0001907108 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 854012572 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 547-9879 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 4 1 form4-12122024_051206.xml X0508 4 2024-12-10 0001907108 Lexeo Therapeutics, Inc. LXEO 0001995218 Townsend Richard Nolan C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010 true true false false Chief Executive Officer 1 Common Stock 2024-12-10 4 M 0 2500 2.33 A 123195 D Common Stock 2024-12-10 4 S 0 2500 8.1965 D 120695 D Stock Option (right to buy) 2.33 2024-12-10 4 M 0 2500 0 D 2031-02-15 Common Stock 2500 118655 D The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. This transaction was executed in multiple trades at prices ranging from $7.98 to $8.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. /s/ Youjin Choi, Attorney-in-Fact 2024-12-11